Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ipratropium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 5/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 7/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 6/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 5/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 0.95 |
| ▸ | BLM | P54132 | 5/20 | 0.79 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.75 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ipratropium SCHEMBL22077027 | 1.00 | CHRM2 (1.00) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| Ipratropium SCHEMBL1476937 | 1.00 | CHRM2 (1.00) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| Ipratropium SCHEMBL1476940 | 1.00 | CHRM2 (1.00) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| Ipratropium SCHEMBL1476943 | 0.99 | CHRM2 (0.98) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| Ipratropium SCHEMBL29152427 | 0.99 | CHRM2 (0.98) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| Ipratropium SCHEMBL3136875 | 0.99 | CHRM2 (0.98) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| Ipratropium SCHEMBL16762661 | 0.99 | CHRM2 (0.98) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| Ipratropium SCHEMBL3852 | 0.99 | CHRM2 (0.98) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| Ipratropium SCHEMBL3854 | 0.99 | CHRM2 (0.98) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| Ipratropium SCHEMBL6854302 | 0.99 | CHRM2 (0.98) | CHRM2CHRM5CHRM1CHRM3CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 196 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3860580-A2 | FORMULATION AND AEROSOL CANISTERS, INHALERS, AND THE LIKE CONTAINING THE FORMULATION | Kindeva Drug Delivery L.P. (US) | 2021-08-11 | — | — | EP | claimed |
| WO-2020070620-A2 | FORMULATION AND AEROSOL CANISTERS, INHALERS, AND THE LIKE CONTAINING THE FORMULATION | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2020-04-09 | — | — | WO | claimed |
| EP-3384909-A1 | COMBINATION OF OXYMETAZOLINE AND IPRATROPIUM IN TOPICAL NASAL APPLICATION FOR THE TREATMENT OF A COUGH | Cortés Borrego, Pablo (MX) | 2018-10-10 | — | — | EP | claimed |
| EP-2978407-A1 | AQUEOUS SOLUTION COMPOSITION CONTAINING IPRATROPIUM AND OXYMETAZOLINE | Santa Farma Ilaç Sanayi A.S. (TR) | 2016-02-03 | — | — | EP | claimed |
| WO-2014158119-A1 | AQUEOUS SOLUTION COMPOSITION CONTAINING IPRATROPIUM AND OXYMETAZOLINE | SANTA FARMA İLAÇ SANAYİ A.Ş (TR) | 2014-10-02 | — | — | WO | claimed |
| WO-2014158118-A1 | SUSPENSION COMPOSITION CONTAINING IPRATROPIUM AND OXYMETAZOLINE | SANTA FARMA İLAÇ SANAYİ A.Ş. (TR) | 2014-10-02 | — | — | WO | claimed |
| US-8450339-B2 | Compositions for treatment of common cold | TAKEDA PHARMA A/S (DK) | 2013-05-28 | — | — | US | claimed |
| US-20110238003-A1 | METHOD FOR SYSTEMIC DRUG DELIVERY THROUGH THE NAIL | NOVARTIS AG (CH) | 2011-09-29 | — | — | US | claimed |
| US-20100137357-A1 | COMPOSITIONS AND METHODS FOR HYPERHIDROSIS | KOLENG JOHN J | 2010-06-03 | — | — | US | claimed |
| WO-2010062930-A1 | COMPOSITIONS AND METHODS FOR HYPERHIDROSIS | DRY PHARMA, LLC (US) | 2010-06-03 | — | — | WO | claimed |
| US-20070287970-A1 | METHOD FOR SYSTEMIC DRUG DELIVERY THROUGH THE NAIL | BRUNO-RAIMONDI ALFREDO E | 2007-12-13 | — | — | US | claimed |
| US-7179849-B2 | Antimicrobial compositions containing colloids of oligodynamic metals | C. R. BARD, INC. (US) | 2007-02-20 | — | — | US | claimed |
| EP-1661570-A2 | Compositions comprising ipatropium and xylometazoline for treatment of the common cold | Nycomed Danmark ApS (DK) | 2006-05-31 | — | — | EP | claimed |
| EP-1446119-B1 | COMPOSITIONS COMPRISING IPATROPIUM AND XYLOMETAZOLINE FOR TREATMENT OF THE COMMON COLD | NYCOMED DANMARK APS (DK) | 2006-03-01 | — | — | EP | claimed |
| US-20050087198-A1 | Method for systemic drug delivery through the nail | BRUNO-RAIMONDI ALFREDO E (CH) | 2005-04-28 | — | — | US | claimed |
| EP-1492512-A1 | METHOD FOR SYSTEMIC DRUG DELIVERY THROUGH THE NAIL | Novartis AG (CH) | 2005-01-05 | — | — | EP | claimed |
| US-20040248924-A1 | Compositions for treatment of common cold | TAKEDA PHARMA A/S (DK) | 2004-12-09 | — | — | US | claimed |
| EP-1446119-A2 | COMPOSITIONS COMPRISING IPATROPIUM AND XYLOMETAZOLINE FOR TREATMENT OF THE COMMON COLD | Nycomed Danmark ApS (DK) | 2004-08-18 | — | — | EP | claimed |
| WO-2003068197-A1 | METHOD FOR SYSTEMIC DRUG DELIVERY THROUGH THE NAIL | NOVARTIS AG (CH) | 2003-08-21 | — | — | WO | claimed |
| WO-2003024433-A2 | COMPOSITIONS FOR TREATMENT OF COMMON COLD, COMPRISING IPRATROPIUM AND XYLOMETAZOLINE | NYCOMED DANMARK APS (DK) | 2003-03-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137357-A1 | COMPOSITIONS AND METHODS FOR HYPERHIDROSIS | CHRM3, ACHE, CHRM5 | CHRM3 1/4885CHRM2 5/4885CHRM5 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.